London. 10 October 2016, 09.00 AM BST. Norgine Ventures announced that it has provided financing of up to €3 million to PulseCath B.V.. This investment recognises the unique positioning of PulseCath’s cardiac assist devices and the growth potential of the company. PulseCath, based in the Netherlands, develops and commercialises innovative left ventricle assist devices. The […]
London, England, June 21, 2016 – Q3 Medical Devices today announced that it has received financing of up to €5million from Norgine Ventures. This investment recognises the growth prospects of Q3 Medical Devices, an Irish based holding company with multiple operations in Germany focused on the development, manufacturing and distribution of minimally invasive devices for […]
London. 17 May 2016, 07:00 am BST. Norgine Ventures announced that it has successfully exited its investment in Stanmore Implants Worldwide Limited (SIW) following the acquisition of SIW by Stryker Corporation (“Stryker”) in an all cash transaction for £35.6m. Stanmore Implants is an orthopaedics company focused on the specialist design and manufacture of patient-specific implants […]
London. 12 January 2015, 09.00 AM GMT. Norgine Ventures today announced that it has successfully exited its investment in Internis Pharmaceuticals Limited following the acquisition of Internis by an undisclosed pharmaceutical company in December 2014. This transaction represents a significant achievement for this exciting and innovative British company. Internis, founded in 2010 by Charles Tannenbaum, […]
London. 3 November 2014, 07:00 AM BST. Norgine Ventures today announced that it has provided financing of €4 million to SpineVision SA. The financing was realised in form of private bonds with warrants. Norgine Ventures is a business entity of Norgine, a European specialist pharmaceutical company. Norgine Ventures’ investment will help SpineVision finance development of […]
London. Monday 13 October 2014. 07:00 AM BST. Norgine Ventures today announced that it has provided financing of up to €7million to Azanta Danmark A/S. This investment recognises the growth prospects of Azanta, a specialty pharma company marketing oncology, women’s health and addiction medicine products. The funding will help Azanta finance its late-stage clinical development […]
